The Chicago-based company got positive test results for several drugs it hopes will fill the void when Humira, the world's top-selling medication, starts facing generic competition in 2023.In a phase 3 clinical trial, AstraZeneca's Anifrolumab, in combination with other medications, was also shown to be effective in treating chronic obstructive pulmonary disease.